JP2008535821A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008535821A5 JP2008535821A5 JP2008503236A JP2008503236A JP2008535821A5 JP 2008535821 A5 JP2008535821 A5 JP 2008535821A5 JP 2008503236 A JP2008503236 A JP 2008503236A JP 2008503236 A JP2008503236 A JP 2008503236A JP 2008535821 A5 JP2008535821 A5 JP 2008535821A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- met
- exon
- stabilized
- over
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003042 antagnostic Effects 0.000 claims 17
- 239000005557 antagonist Substances 0.000 claims 17
- 229920001184 polypeptide Polymers 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 102000004965 antibodies Human genes 0.000 claims 1
- 108090001123 antibodies Proteins 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 claims 1
- 230000006800 cellular catabolic process Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000004059 degradation Effects 0.000 claims 1
- 238000006731 degradation reaction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
Claims (12)
- ヒトの過剰に安定化したｃ-ｍｅｔポリペプチドのｃ-ｍｅｔシグナル伝達活性を阻害するアンタゴニストであって、過剰に安定化したｃ-ｍｅｔポリペプチドがエキソン１４の少なくとも一部を欠失しているために野生型のｃ-ｍｅｔに比べてその分解が減少しており、過剰に安定化したｃ-ｍｅｔポリペプチドがｃ-ｍｅｔシグナル伝達活性を有するものである、アンタゴニスト。
- 前記アンタゴニストが、ヒトｃ-ｍｅｔのエキソン１３とエキソン１５のインフレームスプライシングにより形成されるエピトープに結合する抗体である、請求項１に記載のアンタゴニスト。
- 過剰に安定化したｃ-ｍｅｔポリペプチドのエキソン１４の少なくとも一部が欠失している、請求項１に記載のアンタゴニスト。
- 前記アンタゴニストが、エキソン１３がエキソン１５にスプライスされているｃ-ｍｅｔのスプライス変異体をコードする核酸分子からの発現を優位に抑制する抑制性ＲＮＡである、請求項１に記載のアンタゴニスト。
- 前記アンタゴニストによるｃ-ｍｅｔシグナル伝達活性の抑制が過剰に安定化したｃ-ｍｅｔタンパク質の細胞性分解の亢進を含むものである、請求項１に記載のアンタゴニスト。
- 前記アンタゴニストが毒素に結合している、請求項１に記載のアンタゴニスト。
- 前記アンタゴニストが野生型ｃ-ｍｅｔポリペプチドを特異的に結合しない、請求項１に記載のアンタゴニスト。
- 前記アンタゴニストが野生型ｃ-ｍｅｔポリペプチド活性を実質的に阻害しない、請求項１に記載のアンタゴニスト。
- 請求項１ないし８の何れか一に記載のアンタゴニストを含む、被検体の腫瘍を治療するための医薬。
- 前記腫瘍が過剰に安定化したｃ-ｍｅｔを含むことが決定されている、請求項９に記載の医薬。
- 前記腫瘍が、エキソン１４の少なくとも一部を欠失している変異形ｃ-ｍｅｔを含むことが決定されている、請求項１０に記載の医薬。
- レセプタータンパク質分解を誘導する薬剤と併せてアンタゴニストを含む、請求項９に記載の医薬。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66548205P | 2005-03-25 | 2005-03-25 | |
| PCT/US2006/010850 WO2006104911A2 (en) | 2005-03-25 | 2006-03-24 | Methods and compositions for modulating hyperstabilized c-met |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116934A Division JP2012232979A (ja) | 2005-03-25 | 2012-05-22 | 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008535821A JP2008535821A (ja) | 2008-09-04 |
| JP2008535821A5 true JP2008535821A5 (ja) | 2009-04-09 |
Family
ID=37053941
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503236A Pending JP2008535821A (ja) | 2005-03-25 | 2006-03-24 | 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 |
| JP2012116934A Pending JP2012232979A (ja) | 2005-03-25 | 2012-05-22 | 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012116934A Pending JP2012232979A (ja) | 2005-03-25 | 2012-05-22 | 過剰に安定化したｃ−ｍｅｔを調節するための方法及び組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7615529B2 (ja) |
| EP (1) | EP1868648B1 (ja) |
| JP (2) | JP2008535821A (ja) |
| KR (1) | KR20080000613A (ja) |
| CN (1) | CN101184506B (ja) |
| AU (1) | AU2006229989B2 (ja) |
| BR (1) | BRPI0611468A2 (ja) |
| CA (1) | CA2599988A1 (ja) |
| ES (1) | ES2539790T3 (ja) |
| HK (1) | HK1109075A1 (ja) |
| IL (1) | IL185708A (ja) |
| MX (1) | MX2007011652A (ja) |
| NO (1) | NO20075412L (ja) |
| NZ (1) | NZ561211A (ja) |
| RU (1) | RU2404193C2 (ja) |
| SG (1) | SG159547A1 (ja) |
| WO (1) | WO2006104911A2 (ja) |
| ZA (1) | ZA200707953B (ja) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2404193C2 (ru) * | 2005-03-25 | 2010-11-20 | Дженентек, Инк. | Способ лечения опухоли у субъекта |
| CA2716851A1 (en) * | 2008-03-06 | 2009-09-11 | Genentech, Inc. | Combination therapy with c-met and egfr antagonists |
| CN102164961B (zh) * | 2008-10-01 | 2014-04-16 | 安进研发（慕尼黑）股份有限公司 | 种间特异性PSCAxCD3、CD19xCD3、C-METxCD3、内皮唾液酸蛋白xCD3、EpCAMxCD3、IGF-1RxCD3或FAPαxCD3双特异性单链抗体 |
| PA8849001A1 (es) | 2008-11-21 | 2010-06-28 | Lilly Co Eli | Anticuerpos de c-met |
| EP2417164A1 (en) * | 2009-04-07 | 2012-02-15 | Roche Glycart AG | Bispecific anti-erbb-2/anti-c-met antibodies |
| CN102378768A (zh) * | 2009-04-07 | 2012-03-14 | 罗氏格黎卡特股份公司 | 双特异性抗-ErbB-3/抗-c-Met抗体 |
| KR101736076B1 (ko) | 2009-04-20 | 2017-05-16 | 옥스포드 바이오테라퓨틱스 리미티드 | 카드헤린-１７에 특이적인 항체 |
| KR101671378B1 (ko) * | 2009-10-30 | 2016-11-01 | 삼성전자 주식회사 | ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도 |
| BR112012010153B1 (pt) * | 2009-11-05 | 2022-05-03 | Genentech, Inc | Método de produção de um anticorpo |
| EP3511342B1 (en) | 2010-03-10 | 2024-01-17 | Genmab A/S | Monoclonal antibodies against c-met |
| AU2011318574B2 (en) * | 2010-10-20 | 2016-03-03 | Oxford Biotherapeutics Ltd. | Antibodies |
| AR086823A1 (es) | 2011-06-30 | 2014-01-22 | Genentech Inc | Formulaciones de anticuerpo anti-c-met, metodos |
| MX2014002289A (es) | 2011-08-26 | 2015-03-20 | Merrimack Pharmaceuticals Inc | Anticuerpos fc especificos en tandem. |
| WO2013043452A1 (en) | 2011-09-20 | 2013-03-28 | Eli Lilly And Company | Anti-c-met antibodies |
| WO2013049112A1 (en) * | 2011-09-27 | 2013-04-04 | Emory University | Detection of biomarkers using magnetic resonance |
| KR20130036993A (ko) | 2011-10-05 | 2013-04-15 | 삼성전자주식회사 | ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체 |
| RU2014124842A (ru) * | 2011-11-21 | 2015-12-27 | Дженентек, Инк. | Очистка анти-с-мет антител |
| EP2708556B1 (en) | 2012-09-12 | 2018-11-07 | Samsung Electronics Co., Ltd | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases |
| CN104837502B (zh) | 2012-10-12 | 2018-08-10 | 麦迪穆有限责任公司 | 吡咯并苯并二氮杂卓及其结合物 |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| US20150259430A1 (en) | 2012-11-05 | 2015-09-17 | Mab Discovery Gmbh | Method for the production of multispecific antibodies |
| BR112015021462A2 (pt) | 2013-03-06 | 2017-10-10 | Adimab Llc | anticorpos biespecíficos anti-c-met tandem fc |
| JP6444902B2 (ja) | 2013-03-13 | 2018-12-26 | メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ | ピロロベンゾジアゼピン及びその結合体 |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| US9567641B2 (en) * | 2013-07-03 | 2017-02-14 | Samsung Electronics Co., Ltd. | Combination therapy for the treatment of cancer using an anti-C-met antibody |
| CA2941687A1 (en) | 2014-03-14 | 2015-09-17 | Genentech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| BR112016021383A2 (pt) | 2014-03-24 | 2017-10-03 | Genentech Inc | Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo |
| US10188746B2 (en) | 2014-09-10 | 2019-01-29 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| IL250902B (en) | 2014-09-16 | 2022-08-01 | Symphogen As | Anti-met antibodies and preparations |
| GB201419108D0 (en) * | 2014-10-27 | 2014-12-10 | Glythera Ltd | Materials and methods relating to linkers for use in antibody drug conjugates |
| US20180057595A1 (en) | 2015-03-16 | 2018-03-01 | Celldex Therapeutics, Inc. | Anti-MET Antibodies and Methods of Use Thereof |
| CA3035932A1 (en) | 2016-09-14 | 2018-03-22 | Abbvie Biotherapeutics Inc. | Anti-pd-1 antibodies and their uses |
| EP3525829A1 (en) | 2016-10-11 | 2019-08-21 | Medimmune Limited | Antibody-drug conjugates with immune-mediated therapy agents |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| CN113286616A (zh) | 2018-05-23 | 2021-08-20 | Adc治疗有限公司 | 分子佐剂 |
| BR112021000620A2 (pt) | 2018-07-15 | 2021-04-20 | Enochian BioPharma, Inc. | métodos e composições com uso de células dendríticas recombinantes para terapia contra câncer |
| JOP20210233A1 (ar) | 2019-02-26 | 2023-01-30 | Janssen Biotech Inc | علاجات مركبة وتطابق المريض مع الأجسام ثنائية النوعية المضادة لـ EGFR/c-Met. |
| WO2020230091A1 (en) | 2019-05-14 | 2020-11-19 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors |
| CA3146933A1 (en) | 2019-09-16 | 2021-03-25 | Marcus KELLY | Radiolabeled met binding proteins for immuno-pet imaging |
| WO2022079211A1 (en) | 2020-10-16 | 2022-04-21 | Adc Therapeutics Sa | Glycoconjugates |
| CN114478788A (zh) | 2020-11-11 | 2022-05-13 | 高新 | 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途 |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686292A (en) * | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
| DE69739276D1 (de) | 1996-04-05 | 2009-04-09 | Antonio Giordano | Methoden zur diagnose und prognose von krebs |
| IL127558A0 (en) * | 1996-07-03 | 1999-10-28 | Genentech Inc | Hepatocyte growth factor receptor agonists and uses thereof |
| WO2003088808A2 (en) * | 2002-04-16 | 2003-10-30 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| WO2004072117A2 (en) * | 2003-02-13 | 2004-08-26 | Pharmacia Corporation | Antibodies to c-met for the treatment of cancers |
| EP2093570A1 (en) * | 2003-06-06 | 2009-08-26 | Genentech, Inc. | Modulating the interaction between HGF beta chain and c-met |
| HN2004000285A (es) | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| JP2008507252A (ja) * | 2003-12-11 | 2008-03-13 | ジェネンテック・インコーポレーテッド | Ｃ−ｍｅｔ二量体化及び活性化を阻害するための方法と組成物 |
| ZA200604864B (en) | 2003-12-19 | 2007-10-31 | Genentech Inc | Monovalent antibody fragments useful as therapeutics |
| RU2404193C2 (ru) | 2005-03-25 | 2010-11-20 | Дженентек, Инк. | Способ лечения опухоли у субъекта |
| JP2008533991A (ja) * | 2005-03-25 | 2008-08-28 | ジェネンテック・インコーポレーテッド | 肺癌におけるｃ−ｍｅｔ突然変異 |
-
2006
- 2006-03-24 RU RU2007139452/10A patent/RU2404193C2/ru active
- 2006-03-24 CN CN2006800183951A patent/CN101184506B/zh active Active
- 2006-03-24 CA CA002599988A patent/CA2599988A1/en not_active Abandoned
- 2006-03-24 JP JP2008503236A patent/JP2008535821A/ja active Pending
- 2006-03-24 MX MX2007011652A patent/MX2007011652A/es active IP Right Grant
- 2006-03-24 AU AU2006229989A patent/AU2006229989B2/en active Active
- 2006-03-24 NZ NZ561211A patent/NZ561211A/en unknown
- 2006-03-24 EP EP06748671.2A patent/EP1868648B1/en active Active
- 2006-03-24 WO PCT/US2006/010850 patent/WO2006104911A2/en active Application Filing
- 2006-03-24 KR KR1020077024503A patent/KR20080000613A/ko not_active Application Discontinuation
- 2006-03-24 ZA ZA200707953A patent/ZA200707953B/xx unknown
- 2006-03-24 SG SG201000940-5A patent/SG159547A1/en unknown
- 2006-03-24 ES ES06748671.2T patent/ES2539790T3/es active Active
- 2006-03-24 US US11/388,757 patent/US7615529B2/en active Active
- 2006-03-24 BR BRPI0611468-7A patent/BRPI0611468A2/pt not_active Application Discontinuation
-
2007
- 2007-09-04 IL IL185708A patent/IL185708A/en active IP Right Grant
- 2007-10-24 NO NO20075412A patent/NO20075412L/no not_active Application Discontinuation
-
2008
- 2008-02-18 HK HK08101720.7A patent/HK1109075A1/xx unknown
-
2009
- 2009-09-29 US US12/569,552 patent/US8536118B2/en active Active
-
2012
- 2012-05-22 JP JP2012116934A patent/JP2012232979A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535821A5 (ja) | ||
| Chen et al. | Broad distribution of hepatocyte proliferation in liver homeostasis and regeneration | |
| RU2007139452A (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ МОДУЛИРОВАНИЯ ГИПЕРСТАБИЛИЗИРОВАННОГО c-met | |
| UA116871C2 (uk) | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII | |
| WO2010005566A3 (en) | Notch-binding agents and antagonists and methods of use thereof | |
| JP2012509886A5 (ja) | ||
| PE20061323A1 (es) | Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos | |
| WO2008105886A3 (en) | HUMANIZED FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF | |
| JP2007527865A5 (ja) | ||
| MY159667A (en) | Antibodies to receptor of advanced glycation end products (rage) and uses thereof | |
| MY192113A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
| DE602005026219D1 (de) | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper | |
| JP2009531283A5 (ja) | ||
| IL198379A (en) | Human antibodies and antibodies that bind sphingosine-1-phosphate, their encoded nucleic acids, and their preparations and methods for treating the disease | |
| Andres et al. | Deletion of intestinal epithelial insulin receptor attenuates high-fat diet-induced elevations in cholesterol and stem, enteroendocrine, and Paneth cell mRNAs | |
| JP2006506333A5 (ja) | ||
| NZ596409A (en) | Anti macrophage migration inhibitory factor antibodies | |
| WO2006038027A3 (en) | SINGLE DOMAIN ANTIBODIES AGAINST TNFRl AND METHODS OF USE THEREFOR | |
| JP2014508748A5 (ja) | ||
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| WO2008033395A3 (en) | Melanocortin and transferrin fusion proteins | |
| JP2004532839A5 (ja) | ||
| WO2009142738A3 (en) | Compositions and methods for diagnosing and treating cancer | |
| WO2008034016A3 (en) | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins | |
| JP2015523346A5 (ja) |